MedImmune enters into immuno-oncology clinical trial deal with Juno Therapeutics
The trials will be carried out with one of Juno’s investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune’s investigational programed cell death ligand 1 (PD-L1)